Showing results (431-440 of 440) with videos related to
Sort By:
Pageof 44
You have reached the last page of results.This site can display upto 440 results.
International Journal of Pharmaceutics|June 14, 2000
Novel therapeutic nano-particles (lipocores): trapping poorly water soluble compoundsW R Perkins, I Ahmad, X Li, et al.American Journal of Preventive Cardiology|October 12, 2023
A system approach to improving guideline-directed therapy for cardio-renal-metabolic conditions: The "beyond diabetes" initiativeBenjamin J Hirsh, Jamie S Hirsch, Hosam Hmoud, et al.Development (Cambridge, England)|August 19, 2007
beta-catenin/TCF/Lef controls a differentiation-associated transcriptional program in renal epithelial progenitorsKai M Schmidt-Ott, T Nestor H Masckauchan, Xia Chen, et al.Annals of Internal Medicine|June 1, 1983
Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scanR D Hull, J Hirsh, C J Carter, et al.Journal of Medicinal Chemistry|July 11, 2006
Design, synthesis, and structure-activity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: drugs for cystic fibrosis and chronic bronchitisAndrew J Hirsh, Bruce F Molino, Jianzhong Zhang, et al.Journal of Thrombosis and Haemostasis : JTH|December 29, 2015
Rapid quantitative D-dimer to exclude pulmonary embolism: a prospective cohort management studyS M Bates, S Takach Lapner, J D Douketis, et al.The Journal of Pharmacology and Experimental Therapeutics|January 26, 2008
Pharmacological properties of N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung diseaseAndrew J Hirsh, Jim Zhang, Andra Zamurs, et al.Journal of Thrombosis and Haemostasis : JTH|May 5, 2005
Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control studyJ D Douketis, J A Julian, C Kearon, et al.BMJ (Clinical Research Ed.)|March 12, 2014
Exclusion of deep vein thrombosis using the Wells rule in clinically important subgroups: individual patient data meta-analysisG J Geersing, N P A Zuithoff, C Kearon, et al.Journal of Thrombosis and Haemostasis : JTH|April 22, 2004
Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factorC Kearon, J S Ginsberg, D R Anderson, et al.Pageof 44